- The clinical trial will test the use of ALD-401’s collection of stem cells as a treatment for stroke victims;
- The 100 or so participants in the clinical trial will receive an injection of ALD-401 stem cells 13 to 19 days after suffering a stroke;
- The trial will test the ability of the stem cell therapy to alleviate stroke damage;
- ALD-401 can be delivered about 2 weeks after a stroke and therefore has the potential to treat a large group of patients who have no therapeutic options.
Stroke represents the leading cause of disability in the US and the third leading cause of morbidity.
- The only product currently available for stroke treatment is an anti-clotting agent that must be administered within 3 hours of onset of the stroke;
- Because of this timing requirement, less than 5% of stroke patients receive the treatment.
Aldargen, a Durham, NC drug developer has had an $81M initial public offering pending since fall 2009.